Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR- Mutant Non–Small Cell Lung Cancer
Open accessIntegrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The combination of osimertinib with a MET inhibitor may be beneficial for patients with tumors with MET amplification and T790M.
“suggesting that the combination of osimertinib with a MET inhibitor may be beneficial for such patients.100”
From Afatinib for the treatment of <i>EGFR</i> mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [100]
Cites
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499 · see citing works
Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer
Sequist, L. V., Soria, J.-C., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., Papadimitrakopoulou, V., Solomon, B. J., Oxnard, G. R., Dziadziuszko, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413654 · Cited by 665 · see citing works
Self-citationOu, S.-H. I., Agarwal, N., & Ali, S. M. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.05.015 · Cited by 149 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Afatinib for the treatment of <i>EGFR</i> mutation-positive NSCLC: A review of clinical findings
Harvey, R. D., Adams, V. R., Beardslee, T., & Medina, P. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220931926 · Cited by 115 · see citing works
- Authors
- York, E. R., Varella-Garcia, M., Bang, T. J., Aisner, D. L., & Camidge, D. R.
- Affiliations
- University of Colorado Anschutz (US)
- Corresponding author
- Camidge, D. Ross
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 12
- Issue
- 7
- Pages
- e85-e88
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2594811626
- Cited by
- 76
- References
- 3
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 5 · 2023: 8 · 2022: 12 · 2021: 10 · 2020: 13 · 2019: 9 · 2018: 12 · 2017: 3
- FWCI
- 8.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (P50CA058187)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- crizotinib, osimertinib, MET amplification, EGFR mutation, T790M, L858R mutation, non-small cell lung cancer, adenocarcinoma, pleural effusion, combination therapy, targeted therapy
- MeSH terms
- Crizotinib, Acrylamides, Adult, Aniline Compounds, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Humans, Indoles, Lung Neoplasms, Male, Piperazines, Pyrimidines, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
